Fagron SA
23.25
EUR
-0.40
(-1.69%)
ISIN
BE0003874915
Return %
Stock
S&P 500
1Y
10.45
14.20
3Y
45.68
81.12
5Y
50.68
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Rafael Padilla Papaceit
- Full Time Employees
- 4,134
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Venecoweg 20A Nazareth VL Belgium 9810
- IPO Date
- Oct 5, 2007
- Website
- fagron.com
- Similar Companies
- Business
- Fagron NV (FAGR.BR) is a Belgium-based pharmaceutical compounding company that develops, markets and distributes specialized healthcare products and services to hospitals, pharmacies, clinics and patients worldwide; it operates through three segments including Essentials, which supplies pharmaceutical raw materials, compounding equipment, packaging and supplies; Brands, which offers innovative semi-finished products, pharmaceutical-grade vehicles such as emulsions, creams, Pentravan transdermal bases and SyrSpend oral suspending vehicles, formulations and total concepts; and Compounding Services, which provides sterile and non-sterile ready-to-use personalized compounded medications. Founded in 1990 in Rotterdam, Netherlands, with registered offices in Nazareth, Belgium, operational headquarters in Rotterdam and activities spanning over 30 countries across Europe, North America, Latin America, Asia-Pacific, Africa and other regions, Fagron serves more than 150,000 customers with approximately 4,000 employees. Recent developments include multiple strategic acquisitions in 2025 such as CareFirst Specialty Pharmacy and UCP in North America, Injeplast and Purifarma in Brazil, Amara in Poland, Magilab in Hungary, Bella Corp in Australia, Active Pharma Supplies in the UK and Uni-Chem and SB Trade in Serbia to strengthen market positioning and compounding capabilities; execution of 10 acquisitions in 2025 overall with mid-teens million euro annual revenues at high margins; a new U.S. dollar credit facility for North American growth; expansion investments including a $29 million upgrade to Anazao's 503B facility in Las Vegas for $150 million additional capacity by 2028; and an upgraded growth strategy emphasizing global leadership in essentials, brands acceleration, sterile services expansion and non-sterile optimization presented at its 2025 Capital Markets Day.
Company News
Fagron NV (ARSUF) Q3 2026 Sales/Trading Call Transcript
Fagron NV (ARSUF) Q2 2026 Earnings Call Transcript
Fagron shareholders approve all proposed resolutions at the General Meetings
Fagron NV (ARSUF) Q1 2026 Sales/Trading Call Transcript
Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
Fagron increases share capital through exercise subscription rights
Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript
Fagron NV (ARSUF) Q3 2025 Sales Call Transcript
Fagron: Recent Capital Markets Day Confirms Upside Potential
Fagron: FDA Warning Letter Creates New Entry Opportunity
Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript